LoQus23 Therapeutics nominates LQT-23 as first-in-class, oral drug candidate for Huntington's Disease
PR Newswire —
LQT-23 is a potent, highly differentiated, first-in-class allosteric small molecule inhibitor of MSH3/MutSβ Unique mechanism of action with potential to slow or stop the progression of HD CAMBRIDGE, England, Jan. 6, 2026 /PRNewswire/ -- LoQus23 Therapeutics Ltd ("LoQus23"), a...